CELLVIZIO TECHNOLOGY PLATFORM PRESENTED IN MULTIPLE PROGRAMS AT JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY MEETING

Leading clinicians to highlight applications of Cellvizio confocal laser endomicroscopy during the world's leading medical meeting focused on endoscopy.

PARIS, May 28, 2015 - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today that the Company's Cellvizio technology platform will be highlighted in multiple programs during the 89th Congress of the Japan Gastroenterological Endoscopy Society (JGES), being held May 29-31 in Nagoya, Japan.

"We are very pleased to see the strong emergence of Confocal Laser Endomicroscopy in Japan with the work of leading physicians being presented this year at JGES," said Ichiro Hirata, M.D., Ph.D., President of the 89th Congress of the Japan Gastroenterological Endoscopy Society and Professor of Medicine and Gastroenterology, Fujita Health University, School of Medicine. "There are multiple applications of this advanced technology that are very promising for gastroenterology and we look forward to seeing more and more important publications in the near future."

The goals of the JGES are to promote fundamental and clinical research in the field of gastroenterological endoscopy and to contribute to improvements in human healthcare in Japan and worldwide through academic research. JGES maintains a strong focus on advances in the diagnosis, treatment and prevention of gastrointestinal diseases (primarily gastroenterological cancer) in addition to development of endoscopic devices. During the 2015 JGES Congress, presenters will provide updates on a range of recent clinical developments involving use of Cellvizio confocal laser endomicroscopy, including:

A Keynote Lecture in the JGES Core Session on the "Clinical benefits of optical biopsy with endomicroscopy" by Dr Jean-François Rey, Arnault Tzanck Institute in Saint-Laurent du Var, France;

A lecture on "Endoscopic Ultrasound-Guided needle-Based Confocal Laser Endomicroscopy for Diagnosis of Pancreatic Lesions" by Pr Pradermchai Kongkam, Chulalongkorn University, Bangkok, Thailand;

A lecture on "Experience of probe-based confocal laser endomicroscopy for the diagnosis of biliary strictures", by Dr Senju Hashimoto, Dept. of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan

4 additional lectures on the use of pCLE for gastric tumor, duodenum and colonic lesions.

A Luncheon Seminar on "next-generation diagnostics using probe-based Confocal Laser Endomicroscopy" with Pr. Hisao Tajiri, Professor in the dept. of Innovative Interventional Endoscopy Research, The Jikei University School of Medicine, Tokyo and President of the Japan Gastroenterological Endoscopy Society; Pr. Helmut Neumann, Erlangen University Hospital and Dr Ken Ohata, chief of Endoscopy, NTT Kanto Medical Center, Tokyo, Japan.

"JGES is one of the oldest and most influential gatherings for GI endoscopy in the world, and the strong presence for Cellvizio at the meeting this year is another reflection of the rapidly growing interest in this technology in Japan and throughout Asia," Sacha Loiseau added. "We are especially pleased that so many leading researchers and clinicians in Japan have chosen to highlight recent research related to the impact of Cellvizio in the diagnosis of many GI cancers and conditions, including pancreatic and biliary pathologies."

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on leading innovation in endomicroscopy and optical biopsy.

The company designs, develops and markets innovative tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. The company's flagship product, Cellvizio®, a probe needlebased Confocal Laser Endomicroscopy (pCLE/nCLE) system, provides physicians and researchers with high-resolution cellular imaging of internal tissues. Large-scale, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early forms of diseases and make immediate treatment decisions. Designed to help physicians in their diagnoses, provide patients with better treatment and reduce hospital costs, the Cellvizio system can be used with virtually any endoscope. Cellvizio has 510(k) clearance from the United States Food and Drug Administration and CE Marking in the European Union for use in the gastrointestinal tract and the urinary and respiratory systems, for endoscopic exploration of the biliary and pancreatic ducts and for fine-needle aspiration procedures. Cellvizio has also obtained SFDA regulatory approval in China and MHLW approval in Japan.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies

Eric Cohen

Vice President Finance

Tél. : +33 (0)1 70 08 09 70

investor-vpf@maunakeatech.com

France & Europe

NewCap - Investor Relations Florent Alba / Pierre Laurent Tél. : +33 (0)1 44 71 94 94 maunakea@newcap.fr

United States

Berry & Company Public Relations

Bill Berry

Tel: +1 212 253 8881 bberry@berrypr.com

distributed by